[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cystic-fibrosis-related-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cystic-fibrosis-related-diabetes":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,75,101,125,148,172,212,232,258],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100474852","access-2-ai-for-pediatric-diabetic-eye-exams-study-2-100474852",false,"NCT05463289","ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2","Implementing Digital Retinal Exams Into Comprehensive Pediatric Diabetes Care","ACCESS2","Inclusion Criteria:\n\nMeets American Diabetes Association (ADA) criteria for diabetic retinopathy screening:\n\n* Diagnosis of Type 1 diabetes for ≥3 years, and age 11 or in puberty\n* Diagnosis of Type 2 diabetes\n\nEnriched cohort:\n\n* Patients with Type 1 or Type 2 diabetes,\n* 8-21 years of age with known diabetic retinopathy (true positives).\n* No time limit on last diabetic eye exam.\n\nExclusion Criteria:\n\n* Known diabetic eye exam in the last 12 months","ALL","8 Years","21 Years",{"count":21,"type":22},500,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy, and to determine the diagnostic accuracy of the autonomous AI system in detecting diabetic retinopathy from retinal images of youth with diabetes.",[28,29,30],"Type 1 Diabetes","Type 2 Diabetes","Cystic Fibrosis-related Diabetes",[32],"Diabetic Retinopathy","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2022-07-11",{"date":41,"type":22},"2026-09-30",{"name":43,"class":44},"Johns Hopkins University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100550638","phase-3-bionic-pancreas-in-cfrd-100550638","NCT06449677","Bionic Pancreas in CFRD","A Randomized Trial of the Insulin-only Bionic Pancreas in Cystic Fibrosis Related Diabetes","Inclusion\n\n1. Age ≥ 14 years old at time of signing informed consent\n2. Able to provide informed consent (and assent for participants \\\u003C18 years old)\n3. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:\n\n   * Sweat chloride equal to or greater than 60 mmol\u002Fliter by quantitative pilocarpine iontophoresis test (QPIT) (when not taking a cystic fibrosis transmembrane conductance regulator (CFTR) modulator)\n   * Two well-characterized mutations in the CFTR gene\n4. Clinical diagnosis of CFRD, defined as a person with CF and diabetes mellitus, treated with insulin for ≥3 months prior to screening\n5. Using the same insulin regimen for ≥1 month prior to screening and collection of baseline CGM data, with no plans to change regimen during the study: either multiple daily injections of insulin (MDI), basal-only without bolus insulin, an insulin pump without automation, or an automated insulin delivery (AID) system other than the BP (which is an exclusion)\n6. Total daily insulin dose must be ≥0.1 units\u002Fkg\n7. Able to speak and read English sufficient to understand the pump user interface and provide written materials for safe operation of the BP\n\n   • For pediatric participants, this applies to both the participant and caregiver\n8. For participants \\\u003C18 years old, living with one or more parent\u002Flegal guardian knowledgeable about emergency procedures for severe hypoglycemia. A designated care partner must be willing to be linked to the participant's Dexcom Follow application with location sharing on.\n9. For participants \\>18 years old who live alone, participant has a relative or acquaintance who lives within 30 minutes of participant and is willing to be contacted to check on participant if study staff feel that participant may be experiencing a medical emergency and cannot be reached. A designated care partner must be willing to be linked to the participant's Dexcom Follow application with location sharing on.\n10. No use of a non-insulin glucose-lowering medication, except metformin, that is not approved for use in T1D within 3 months prior to signing informed consent and willing to not use any such medications during the course of the trial. Note: such drugs cannot be used even if prescribed for weight loss rather than glucose-lowering.\n11. If not currently using a rapid-acting insulin that is approved for use in the iLet pump, willing and able to switch to an approved insulin when using the BP.\n12. Participant has commercial glucagon available for treatment of severe hypoglycemia or will obtain it prior to randomization\n13. Willing to authorize the study team to contact the participant's primary physician to inform them about their participation in this study.\n14. Enrolled in the Cystic Fibrosis Foundation Patient Registry (participants may enroll in the Registry at the time of enrollment if not already enrolled).\n15. No plans for trips of more than 14 consecutive days outside the United States during the period of study participation\n16. Investigator believes that the participant can safely use the iLet and will follow the protocol • The investigator will take into account the participant's HbA1c level (there is no upper limit for eligibility), compliance with current diabetes management, prior acute diabetic complications, cognitive ability, and general medical condition. For this reason, there is no upper limit on HbA1c specified for eligibility.\n\nExclusion\n\n1. Current use of the BP or an AID system not FDA approved for T1D\n2. Known hemoglobinopathy (sickle cell trait is not an exclusion)\n3. Current participation in another diabetes-related interventional trial\n4. Established history of allergy or severe reaction to adhesive or tape that must be used in the study\n5. Pregnant (positive urine hCG), breast feeding, plan to become pregnant in the next 7 months, or sexually active and can become pregnant but not using contraception\n6. Current use of hydroxyurea or unable to avoid hydroxyurea use during the study (interferes with accuracy of Dexcom sensor)\n7. Have started or stopped a CFTR modulator in the 4 weeks prior to screening.\n\n   • Modifications of the dosing of a CFTR modulator is acceptable\n8. Anticipated lung or liver transplant (on transplant list)\n9. Lung or liver transplant within one year prior to screening. If they have had a transplant more than a year ago, but they:\n\n   * Have had a rejection episode occur in prior 8 weeks, individual is excluded.\n   * Their doses of corticosteroids and\u002For calcineurin inhibitors have not been stable for one month prior to enrollment and\u002For is expected to change significantly over the course of the study, individual is excluded.\n10. Acute pulmonary exacerbation or hospitalization within the 4 weeks prior to screening or treatment with IV antibiotics in the 4 weeks prior to screening\n11. History of a complete pancreatectomy\n12. Currently using enteral tube feedings for nutritional support\n13. Presence of a medical condition or use of a medication that, in the judgment of the investigator, clinical protocol chair, or medical monitor, could compromise the results of the study or the safety of the participant. Conditions to be considered by the investigator may include the following:\n\n    * Alcohol or drug abuse\n    * Use of prescription drugs that may dull the sensorium, or hinder decision-making during the period of participation in the study such has opioids or short-acting benzodiazepines\n    * Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g., climbing a flight of stairs) despite medical management; or within the last 12 months before screening: a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting\n    * Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV\n    * History of TIA or stroke in the last 12 months\n    * Severe liver disease such as end-stage cirrhosis\n    * Renal failure requiring dialysis or known eGFR \\\u003C30\n    * Untreated or inadequately treated mental illness\n    * History of untreated or inadequately treated eating disorder within the last 2 years, such as anorexia, bulimia, or diabulimia or omission of insulin to manipulate weight\n    * History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment\n14. Employed by, or having immediate family members employed by Beta Bionics, or being directly involved in conducting the clinical trial, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial.","14 Years",{"count":55,"type":22},150,[57],"PHASE3","This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system.",[30],[61,62,63,64],"Cystic fibrosis-related diabetes (CFRD)","iLet bionic pancreas","Automated insulin delivery","Continuous glucose monitoring","2026-06-23",{"date":67,"type":37},"2026-06-24",{"date":69,"type":37},"2024-09-24",{"date":71,"type":22},"2027-03-30",{"name":73,"class":44},"Jaeb Center for Health Research",16,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100600788","glucose-metabolism-in-cystic-fibrosis-related-diabetes-cfrd-100600788","NCT07102043","Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)","Glucose Metabolism in CFRD: Exploring the Role of CFTR Modulators in Metabolic Dysfunction","Inclusion Criteria:\n\n1. Diagnosis of Cystic Fibrosis Related Diabetes (CFRD)\n2. Age 21-75 years at time of consent\n3. BMI 19-50 kg\u002Fm2 (In Asians BMI is \\~ 2 points lower for comparison so it is 17-48 kg\u002Fm2)\n4. Creatinine ≤ 1.4 mg\u002Fdl in women and ≤ 1.5 mg\u002Fdl in men\n5. HbA1c ≤ 11% lifestyle treatment or mono\u002Fcombination therapy with oral hypoglycemic agents (e.g. metformin or sulphonylurea or SGLT2i) and preferably on insulin pump therapy (i.e., SAP, HCL) with or without CGM will be recruited. However, use of MDI (Multiple Daily Injections) of insulin, i.e., on basal-bolus insulin therapy will also be included. Most of our patients are on insulin therapy with very few on oral antidiabetes medications but we would like to offer them the choice of participation.\n6. Subjects on FDA approved\u002Frecommended full doses of ETI will be offered participation. If dose adjustments of ETI are made after enrollment a discussion will be done with the primary care provider and HCSTOC as required.\n7. Willing to be at a stable weight for duration of the study.\n8. An understanding of and willingness to follow the protocol and sign the informed consent\n\nSubjects meeting any of the exclusion criteria at baseline will be excluded from study participation:\n\nExclusion Criteria:\n\n1. Debilitating chronic disease\n2. Anemia \\\u003C10.0 gm\u002FdL in females and \\\u003C11.0 gm\u002FdL in males\n3. Symptoms of undiagnosed illness on history\u002Fexam\n4. Abuse of alcohol or recreational drugs\n5. Pregnancy\n6. Active hepatic disease (we will include only if less than 3X ULN for liver enzymes and no fibrosis on ultrasound). Transient elevations of liver enzymes will not exclude participation but will be discussed with the primary care provider and HCSTOC as required.\n7. Current use of the following drugs and supplements:\n\n   i. Corticosteroids ii. Benzodiazepines iii. Opiates iv. Barbiturates v. Anticoagulant therapy vi. Any other medication that the investigator believes is a contraindication to the subject's participation","75 Years",{"count":84,"type":22},30,"OBSERVATIONAL","The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR modulator (ETI) therapy (CFRDF508del+ETI). CFRD with a mutation that is not eligible for modulator therapy (CFRD-ETI) will be the control group.",[88],"Cystic Fibrosis Related Diabetes",[88,90,91,92],"cystic fibrosis transmembrane conductance regulator (CFTR)","CFTR modulators","Elexacaftor\u002F tezacaftor\u002Fivacaftor or ETI","2026-06-19",{"date":67,"type":37},{"date":96,"type":37},"2026-05-28",{"date":98,"type":22},"2028-05-28",{"name":100,"class":44},"University of Alabama at Birmingham",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100498170","feed-cystic-fibrosis-feed-cf-100498170","NCT05766774","FEED-Cystic Fibrosis (FEED-CF)","Feeding Study to Optimize Endocrine Dysfunction in Cystic Fibrosis","FEED-CF","Inclusion Criteria:\n\n1. Confirmed CF diagnosis\n2. Ages 18 years and older\n3. Baseline estimated daily total added sugar intake \\>16 tsp, as estimated from the Dietary Screener Questionnaire (DSQ).\n\nExclusion Criteria:\n\n1. Nocturnal tube feeds\n2. BMI \\\u003C18.5 kg\u002Fm2\n3. Life expectancy \\\u003C 12 months\n4. Confirmed diagnosis of CFRD\n5. Screening OGTT showing fasting hyperglycemia (≥126 mg\u002FdL)\n6. Chronic steroid use\n7. Current pregnancy or lactation\n8. Inability\u002Funwillingness to consume the majority of foods on the menu during the study period\n9. MRI-incompatible metal that cannot be removed for testing\n10. Uncontrolled exocrine pancreatic insufficiency\u002Fmalabsorption\n11. Clinically instability, defined as no changes in medical regimen (including medications and pulmonary exacerbations) for at least 21 days prior to study visit\n12. Initiation of CFTR modulator within previous 8 weeks OR unstable changes in weight and lung function due to CFTR modulator use\n13. Actively trying to gain or lose weight\n14. Any food allergies or intolerances that cannot be accommodated\n15. Any medical condition deemed by the a study physician or PI that may preclude completion of the study or interfere with primary end points.","18 Years",{"count":111,"type":22},60,[25],"The goal of this study is to determine the extent to which excess dietary sugars serve as a precipitating factor in glucose intolerance in adults with cystic fibrosis (CF), a population at especially high risk for a unique form of diabetes (CF-related diabetes, CFRD) and with standard-of-care dietary recommendations (high-calorie, high-fat) that conflict with recommendations for other forms of diabetes.\n\nThis trial will investigate if the typical high-sugar, high-fat CF diet plays a role in diabetes risk and visceral fat accumulation in people with CF. A total of 30 participants will get a low-added sugar, high-fat diet and the other 30 will get a standard CF diet with no sugar restrictions. Participants will be randomized to the diet group they are assigned. All foods will be provided for 8 weeks.",[115,30],"Cystic Fibrosis","2026-06-01",{"date":118,"type":37},"2026-06-03",{"date":120,"type":37},"2023-06-28",{"date":122,"type":22},"2028-06-30",{"name":124,"class":44},"Emory University",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":45},"100403214","phase-2-metformin-for-people-with-cfrd-on-cftr-modulator-therapy-to-improve-ion-channel-function-100403214","NCT04530383","Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function","An Open Label Clinical Trial of Metformin in Those With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function","Inclusion criteria:\n\n1. Age \\>18 years with a prior diagnosis of CF.\n2. Use of ivacaftor or elexacaftor\u002Ftezacaftor\u002Fivacaftor or vanzacaftor\u002Ftezacaftor\u002Fdeutivacaftor for 30 days prior to day 0\n3. Diagnosis of CFRD with evidence of continued glucose intolerance at least 6 months after starting qualifying modulator therapy will be based upon one of the following:\n\n   1. Insulin use\n   2. Hemoglobin A1C \\>6.5%\n   3. Fasting glucose \\>126 mg\u002Fdl\n   4. Non-fasting glucose \\>200 mg\u002Fdl (random or as part of a 2-hr OGTT)\n\nExclusion criteria:\n\n1. Prior lung or liver transplant\n2. Use of supplemental oxygen\n3. BMI \\\u003C18\n4. CF pulmonary exacerbation requiring hospitalization or intravenous antibiotics in the preceding 30 days\n5. Systemic corticosteroid or regular non-steroidal anti-inflammatory use in the preceding 30 days\n6. Cardiac, renal (creatinine clearance \\\u003C45 mL\u002Fminute), neurologic, psychiatric, endocrine or neoplastic diseases that are judged to interfere with participation in the study\n7. Alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase \\>1.5X the upper limit of normal; bilirubin \\>3 mg\u002FdL\n8. Taking medications that interact with metformin.\n9. Vitamin B12 deficiency\n10. Pregnancy or lactation\n11. Inability or unwillingness to comply with an approved contraceptive method during the study period (females of childbearing age)\n12. Use of medications known to be strong CYP inducers or moderate to strong CYP inhibitors\n13. In the opinion of the investigator any severe or acute or chronic condition or laboratory abnormality that may increase the risk associated with trial participation or make the subject inappropriate for enrollment\n14. Participation in another interventional trial that, in the opinion of the investigator, has the potential to affect the primary outcome",{"count":84,"type":22},[134],"PHASE2","The purpose of this study is to assess the efficacy of metformin to improve airway ion channel function in those with CF-related diabetes (CFRD)",[30,115],[138],"Metformin","2026-04-10",{"date":141,"type":37},"2026-04-15",{"date":143,"type":37},"2022-02-14",{"date":145,"type":22},"2028-07-15",{"name":147,"class":44},"University of Kansas Medical Center",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100592609","phase-1-dorzagliatin-in-pancreatic-insufficient-cystic-fibrosis-100592609","NCT06995651","Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis","Pharmacokinetic and Pharmacodynamic Effects of Dorzagliatin in Pancreatic Insufficient-Cystic Fibrosis: A Randomized Double-blind, Cross-over Trial","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female, aged ≥18 years on date of consent.\n4. Confirmed diagnosis of CF, defined by positive sweat test or CFTR mutation analysis according to CFF diagnostic criteria.\n5. Pancreatic insufficiency defined by clinical requirement for pancreatic enzyme replacement.\n6. Abnormal glucose tolerance defined by OGTT criteria for EGI, IGT, or CFRD, or diagnosed CFRD.\n7. There will be no restriction on enrollment of individuals with CFRD but without fasting hyperglycemia (fasting hyperglycemia is defined as fasting glucose ≥126 mg\u002FdL)\n\n   a. Individuals with CFRD and fasting hyperglycemia (defined as above or by the use of basal insulin therapy) must also have a HbA1c ≤8% and a random (non-fasting) C- peptide ≥1.2 ng\u002FmL \\[15\\].\n8. For females of reproductive potential: use of highly effective contraception method for the during of study participation; oral contraceptives, intra-uterine devices, Norplant®, Depo- Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.\n\nExclusion Criteria:\n\n1. Established diagnosis of non-CF diabetes (e.g. type 1 diabetes).\n2. Pregnancy or lactation; a negative urine pregnancy test will be required at enrollment.\n3. Pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids within 4 weeks prior to randomization.\n4. Treatment with either CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, indinavir, ritonavir, saquinavir, telithromycin, boceprevir, nelfinavir, telaprevir, conivaptan, nefazodone, etc.) or inducers (e.g. phenobarbital, other barbiturates, carbamazepine, phenytoin, rifampicin, dexamethasone, etc.).\n5. Use of herbal remedies, including St. John's Wort within 14 days prior to dosing.\n6. Change in CFTR modulator therapy in the previous 3 months.\n7. History of clinically symptomatic pancreatitis within the last year.\n8. Prior lung, liver or another solid organ transplant.\n9. Abnormal kidney function: creatinine \\>2x upper limit of normal (ULN) or potassium \\>5.5mEq\u002FL on non-hemolyzed specimen.\n10. Abnormal liver function: persistent elevation of liver function tests \\>2.0 times ULN.\n11. Uncontrolled hyperlipidemia: triglycerides \\>500 or cholesterol \\>250 mg\u002Fdl.\n12. Hyperuricemia: serum uric acid \\>1.5 times ULN.\n13. Anemia: hemoglobin \\\u003C10 g\u002FdL.\n14. History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject.",{"count":156,"type":22},15,[158],"PHASE1","This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance when compared to randomized, double-blind 7-day administration of placebo in a cross-over fashion. We hypothesize that dorzagliatin administration will result in significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage assessed during a standardized mixed-meal tolerance test.",[161,30],"Pancreatic Insufficiency","2026-04-03",{"date":164,"type":37},"2026-04-09",{"date":166,"type":37},"2025-10-21",{"date":168,"type":22},"2027-07",{"name":170,"class":44},"University of Pennsylvania",2,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":179,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":182,"conditions":183,"keywords":192,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":211},"100580429","studying-the-presence-of-cfrd-complications-with-thoughtful-recruitment-spectrum-100580429","NCT06837181","Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)","SPeCTRuM","Inclusion Criteria:\n\n* Written informed consent (and assent when applicable) obtained from participant or participant's legally authorized representative\n* For Adults: Must be able to consent on one own's behalf (i.e., cannot lack cognitive capacity to consent due to the required patient-reported outcomes)\n* Be willing and able to adhere to the study protocol requirements\n* Age ≥ 12 years at time of enrollment\n* CF diagnosis based on two CF causing mutations and\u002For positive sweat test according to CFF diagnostic criteria\n* CFRD diagnosis ≥ 5 years at time of enrollment\n\nExclusion Criteria:\n\n* History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject\n* History of transplant\n* Pregnancy reported by participant at time of consent or at any point during active study participation\n\nPulse Wave Velocity Exclusion Criteria:\n\n* Erratic, accelerated or mechanically controlled irregular heart rhythms including arrhythmias\n* Carotid or aortic valve stenosis\n* Peripheral artery disease or leg artery disease\n* Generalized constriction or localized spasm of muscular conduit arteries such as seen immediately after hypothermic cardiopulmonary bypass surgery or accompanying Raynaud's phenomena or intense cold.\n* Possible exclusions based on investigator medical provider assessment (additional precautions may be followed to allow inclusion):\n\n  * Pressure reading should not be conducted on a limb where there is intravenous access, arterio-venous shunt, or where circulation is compromised.\n  * Pressure reading should not be conducted on the side of the body that a mastectomy was done.","12 Years",{"count":181,"type":22},200,"This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF.\n\nThe overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people with established CFRD.",[184,30,185,186,187,188,189,190,191],"Cystic Fibrosis (CF)","Diabetes","Retinopathy","Neuropathy","Nephropathy","Blood Pressure","Cardiovascular Risk","Microvascular",[115,193,194,195,196,64,197,185,198,199,200,201,202],"CFRD","Cystic Fibrosis-Related Diabetes","Observational","Physical Activity Tracker","CGM","blood pressure","cardiovascular risk","microvascular","diabetes complications","social determinants of health","2026-02-09",{"date":205,"type":37},"2026-02-10",{"date":207,"type":37},"2025-09-18",{"date":209,"type":22},"2028-11-30",{"name":73,"class":44},18,{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":45},"100559156","continuous-glucose-monitoring-and-ogtt-screen-for-cystic-fibrosis-related-diabetes-in-cystic-fibrosis-100559156","NCT06560463","Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis","Comparison of Continous Glucose Monitor and OGTT as a Screen for Cystic Fibrosis Related Diabetes and Impaired Glucose Tolerance","Inclusion Criteria:\n\n1. An adult patient, diagnosed with CF, established with Froedtert Multidisciplinary CF Clinic.\n2. Normal glucose tolerance or impaired glucose tolerance per OGTT completed in 2024.\n3. At healthy baseline status at time of CGM wear and OGTT.\n\nExclusion Criteria:\n\n1. Diagnosed with CFRD and treating with diabetogenic medications.\n2. s\u002Fp transplant\n3. pregnancy\n4. failure to wear CGM for entirety of 10 days",{"count":84,"type":22},"Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes. The diagnosis of CFRD is associated with a decline in pulmonary function, decreased nutritional status, and increased mortality. CFRD is extremely common in people with CF, occurring in approximately 40-50% of adults with CF. Impaired glucose tolerance or dysglycemia is also very common in CF. It is standard of care to screen for CFRD annually from the age of 10 years with a two-hour Oral Glucose Tolerance Test (OGTT) with 75 g dextrose. The gold standard screening for CFRD is the OGTT which is problematic as it is time consuming for patient and staff and adherence to annual screening is low among CF centers.\n\nSurvival has improved dramatically with the advent of CFTR modulators and it is presumed that the incidence of CFRD will increase with increased life expectancy. The Cystic Fibrosis Foundation (CFF) has developed the oldest disease specific patient registry, consisting of approximately 35000 patients, so there is vast historical information available on individual patients and larger datasets on the CF community as a whole. Based on the 2021 CFF patient registry data, the current life expectancy for CF patients born between 2017 and 2021 is 53 years - a 15 year increase from a decade ago.",[30,115],[223],"cystic fibrosis","2025-08-26",{"date":226,"type":37},"2025-09-03",{"date":228,"type":37},"2025-01-13",{"date":41,"type":22},{"name":231,"class":44},"Medical College of Wisconsin",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":171},"100494843","the-effects-of-a-low-glycemic-load-diet-on-dysglycemia-and-body-composition-in-adults-with-cystic-fibrosis-related-diabetes-100494843","NCT05723445","The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes","DINE","Inclusion Criteria:\n\n* 18 years and above\n* Genetically confirmed diagnosis of CF\n* Diagnosis of pancreatic insufficiency, requiring pancreatic enzyme replacement\n* Criteria for CFRD:\n\nA.) Most recent OGTT 2-hour glucose \\>200 mg\u002FdL within the past two years, and\u002For; B.) HbA1c \\>6.5% in the past two years, and\u002For; C.) Current use of insulin\n\nExclusion Criteria:\n\n* FEV1 \\\u003C50% predicted on most recent pulmonary function testing\n* BMI \\\u003C18 kg\u002Fm2\n* Currently receiving enteral nutrition support via GT feeds\n* Pregnancy, plan to become pregnant in the next 3-months, or sexually active without use of contraception\n* Use of IV antibiotics or systemic supraphysiologic glucocorticoids for CF exacerbation within 1 month\n* Started or stopped treatment with a CFTR modulator within 3 months of enrollment\n* Currently adhering to an LGL or other carbohydrate-restricted diet (carbohydrate intake \\\u003C30% of total daily caloric intake)","70 Years",{"count":156,"type":22},[25],"This study will evalute the effect of a low glycemic load (LGL diet on dysglycemia, insulin requirements, DXA-derived body composition, gastrointestinal symptoms and quality of life measures in adults with cystic fibrosis-related diabetes (CFRD). We will use continuous glucose monitors (CGM) to assess the LGL diet both in a controlled setting (via a meal delivery company) and in free-living conditions.",[115,30,244],"Cystic Fibrosis With Intestinal Manifestations",[194,246,247,248],"Low Glycemic Load","Continuous Glucose Monitoring","Body Composition","2025-08-16",{"date":251,"type":37},"2025-08-22",{"date":253,"type":37},"2023-09-01",{"date":255,"type":22},"2026-07-01",{"name":257,"class":44},"Rhode Island Hospital",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":179,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":278,"locationsCount":45},"100565471","cgm-dynamic-index-for-predicting-prediabetes-in-cystic-fibrosis-100565471","NCT06642610","CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis","CGM Dynamic Index (CDI) for Predicting Prediabetes in People With Cystic Fibrosis","Inclusion Criteria:\n\n* CF individuals aged 12-55 years.\n* CF without diabetes or with prediabetes (as defined by OGTT and HbA1c).\n* Willing to use a continuous glucose monitoring system with compatible smart phone for glucose data collection.\n\nA person with CFRD and already using CGM, we will just collect their personal CGM data, and they are not required to have OGTT or HbA1c visit.\n\nExclusion Criteria:\n\n* Pregnancy.\n* History of transplant.\n* Use of immunosuppressant drugs.\n* Use of oral steroids or any medication known to interfere with glucose.\n* Allergy to adhesives.\n* Individuals with severe concurrent medical conditions that could confound glucose monitoring data (e.g., terminal illness, major organ failure).\n* Conditions that may make unsafe for participants to do study or impair or confound the study at the discretion of the investigator","55 Years",{"count":267,"type":22},70,[25],"The primary objective of this pilot study is to develop a CGM-based model to predict the progression from prediabetes to diabetes in individuals with cystic fibrosis.",[271,184,30],"Prediabetes","2025-07-27",{"date":274,"type":37},"2025-07-29",{"date":276,"type":37},"2025-06-15",{"date":34,"type":22},{"name":279,"class":44},"Indiana University"]